Zura Bio Ltd (ZURA) Form S-3 — Oct 27, 2026
Zura Bio filed a $700 million universal shelf registration statement covering Class A ordinary shares, preference shares, debt securities, warrants and units, alongside a sales agreement prospectus for up to $114,044,900 of Class A ordinary shares in an at-the-market offering through Leerink Partners. The Sales Agreement, originally dated September 3, 2024, was amended on October 27, 2026 and raised to $125 million total capacity, of which $10.96 million has already been sold. Leerink earns a 3.0% commission and shares would be sold at prevailing market prices, with the last reported sale at $3.56 on October 26, 2026.
Key figures
- Gross Proceeds
- 114044900
- Offering Price
- 3.56
- Shares Offered
- up to $114,044,900 of Class A Ordinary Shares (approx. 32,035,084 shares at $3.56 assumed price)
- Shares Outstanding
- 96325411
- Atm capacity
- $125,000,000 total Sales Agreement capacity; $10,955,100 already sold; $114,044,900 remaining
- Shelf capacity
- $700,000,000 base shelf across Class A Ordinary Shares, preference shares, debt securities, warrants and/or units
- Dilution per share
- $1.32 to new investors at assumed $3.56 price
- Last sale price date
- October 26, 2026
- Sales agent commission
- 3.0% of gross sales price
- Pre funded warrant shares
- 29295396
- Net tangible book value per share
- $1.84 as of September 30, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.